Industries
AI Pharmaceuticals (AI Drug Discovery)
Toutes les analyses de AI Pharmaceuticals (AI Drug Discovery) — 6 analyses.
36/100
Recursion Pharmaceuticals: A Sub-$375m Cost Reset Buys Runway into Early 2028, but $3.63 Already Pays for About 66% of a $1.28bn Platform Option
Recursion is a clinical-stage TechBio company that sells discovery work, milestones and prospective royalties to pharmaceutical partners while funding an internally owned small-molecule pipeline, with no approved-product revenue. Q2 2026 total revenue of $7.67m sat below $11.49m of cost of revenue and a further $131m of R&D and G&A, yet management cut FY2026 cash operating expense guidance to below $375m and $556.8m of cash and restricted cash funds operations into early 2028; the headline 43% REC-4881 polyp reduction was disclosed in December 2025, not August 2026, so the post-June rebound was re-rating rather than clinical de-risking. Rating Watch: base intrinsic value is $4.40 against the $3.63 close, but the $2.80 conservative case sits below today’s price, leaving no margin of safety and an ideal buy zone of $1.90-2.20.
35/100
Absci Corporation: The Platform Is Real, but the Price Already Bets Big on ABS-201
Absci is a clinical-stage biotech that uses generative AI, proprietary high-throughput lab data, and wet-lab validation cycles to design antibodies, but current revenue still comes almost entirely from small, lumpy partnered discovery fees rather than owned products. FY2025 revenue was just $2.8 million and fell further to $0.2 million in Q1 2026, while the June 2026 announcement of positive interim Phase 1 safety data for lead asset ABS-201 (androgenetic alopecia) let the company raise $100 million, including a $40 million allocation from Eli Lilly, at $7.41 a share. Rating Hold: the platform and early clinical data are genuinely more credible than a year ago, but at $7.56 the stock already sits near a roughly $1.2-1.3 billion valuation on almost no current revenue, leaving little room for anything short of a strong ABS-201 efficacy readout.
34/100
Generate Biomedicines: The Asset Is Real, the AI Premium Is Still on Trial
Generate Biomedicines is a clinical-stage generative-biology company designing AI-generated protein therapeutics, funding its lead Phase 3 severe-asthma asset GB-0895 from Novartis and Amgen collaboration revenue and a post-IPO cash balance of $516.6 million as of March 2026. The core tension: Q1 2026 collaboration revenue fell to $7.2 million from $8.8 million a year earlier while net loss widened to $61.7 million and operating cash burn reached $80.4 million, so nearly all of the company's value now rests on one late-stage asset that will not complete enrollment until the first half of 2028, even as the stock still trades about 13% below its February 2026 IPO price. Rating Hold: the platform science and cash runway are real, but at $13.90 the market has already priced in a meaningful share of GB-0895's eventual success, leaving little margin of safety for new capital.
44/100
AbCellera Biologics: A Well-Funded Platform Waiting on One Clinical Proof Point
AbCellera Biologics is a clinical-stage antibody company transitioning from a partner-fee-and-royalty platform to owning its own drug pipeline, anchored by lead candidate ABCL635 heading into Phase 2 data. FY2025 revenue reached $75.1 million but the company still lost $146.4 million, leaving about $655 million of liquidity to fund the transition. Rating Watch: a well-capitalized platform that still needs ABCL635's Q3 2026 efficacy readout before the transition story can be trusted.
49/100
XtalPi Holdings: An AI-for-Science Platform Climbing from Fee-for-Service Work to Milestone Economics, Still Priced Ahead of Proof
XtalPi is a founder-led AI-for-science platform built by MIT-trained physicists, selling drug-discovery and R&D-automation solutions as it tries to climb from fee-for-service work toward milestone-and-royalty economics. 2025 revenue jumped 201.2% to RMB802.6 million as drug-discovery solutions rose to RMB537.9 million from RMB103.7 million, but one customer was over 45% of sales, reported profit leaned on RMB514.0 million of fair-value gains, and operating cash flow stayed negative at RMB-165.4 million. Rating Hold: serious science with blue-chip partners (DoveTree, Lilly, Pfizer) and a large cash cushion, yet the price still pays for cleaner, broader earnings than the platform has delivered; the ideal buy zone is HK$3.8-4.1.
39/100
Recursion Pharmaceuticals: A Zen Horizon Framework Deep Dive
Recursion Pharmaceuticals (RXRX.US) is the flagship AI drug-discovery name: the largest and most broadly integrated AI-native drug company globally, with Exscientia added in 2024 to fill the precision-chemistry gap. The core thesis is a hybrid of an AI drug-discovery platform and an in-house biotech pipeline, backed by deep partnerships with NVIDIA, Roche/Genentech, Bayer, Sanofi, and others, yet still dependent on unpredictable collaboration milestones with no product revenue. Report rating Watch: real infrastructure assets and a heavily reset valuation deserve close tracking, but NVIDIA exited its stake by the end of 2025 and founder CEO Chris Gibson has stepped down while the platform remains clinically unproven.